Allergic Conjunctivitis In Dogs: Comprehensive Veterinary Reference Guide

Introduction

Allergic conjunctivitis in dogs is one of the most frequently encountered ophthalmic conditions in small animal practice. Characterised by inflammation of the conjunctiva (the mucous membrane lining the eyelids and covering the anterior sclera), this condition arises from an exaggerated immune response to environmental allergens. While rarely vision-threatening, allergic conjunctivitis causes significant discomfort, including pruritus, epiphora (excessive tearing), and ocular discharge. This comprehensive reference guide provides an exhaustive, clinically detailed overview of allergic conjunctivitis in dogs, covering aetiology, pathophysiology, clinical presentation, diagnostic approach, medical management, and preventive strategies. It is designed for veterinary professionals, veterinary students, and informed pet owners seeking a deep understanding of this common disorder.

This article adheres to global veterinary consensus guidelines, including those from the American Veterinary Medical Association (AVMA), the American Animal Hospital Association (AAHA), the Canadian Veterinary Medical Association (CVMA), the Australian Veterinary Association (AVA), and the Federation of Veterinarians of Europe (FVE). Regional variations in allergen prevalence, diagnostic availability, and treatment protocols are highlighted to ensure relevance for a global audience.

Quick Q&A

Question: What is the best way to treat allergic conjunctivitis in dogs at home? Answer: While home care can provide temporary relief, the most effective treatment for allergic conjunctivitis in dogs requires veterinary diagnosis. Your veterinarian may recommend preservative-free artificial tears, cold compresses, and oral antihistamines, but prescription medications such as topical corticosteroids or immunomodulators (e.g., cyclosporine) are often necessary. Never use human eye drops containing vasoconstrictors or steroids without veterinary guidance, as these can cause serious side effects.

Anatomy and Physiology of the Canine Conjunctiva

The conjunctiva is a thin, transparent, vascularised mucous membrane that lines the inner surface of the eyelids (palpebral conjunctiva) and reflects onto the anterior sclera (bulbar conjunctiva), forming the conjunctival fornices. It contains goblet cells that secrete mucin, a critical component of the precorneal tear film, contributing to ocular surface lubrication and immune defence. The conjunctiva is rich in lymphoid tissue (conjunctiva-associated lymphoid tissue, or CALT), making it an active site for immune surveillance and a primary target for allergic inflammation.

In allergic conjunctivitis, the conjunctival vasculature dilates, leading to hyperaemia (redness), chemosis (oedema), and increased production of serous or mucoid discharge. The presence of mast cells, eosinophils, and lymphocytes in the conjunctival stroma underscores the allergic aetiology. Understanding this anatomy is essential for differentiating allergic conjunctivitis from other causes of red eye, such as keratitis, uveitis, glaucoma, or dry eye (keratoconjunctivitis sicca, KCS).

Aetiology and Pathophysiology

Allergic Triggers

Allergic conjunctivitis in dogs is typically an immediate (Type I) hypersensitivity reaction mediated by immunoglobulin E (IgE). Common environmental allergens include:

• Pollen: Grass, tree, and weed pollens (seasonal allergens).
• House dust mites: Dermatophagoides farinae and D. pteronyssinus are perennial allergens.
• Mould spores: Alternaria, Aspergillus, Cladosporium.
• Animal dander: From other pets or humans.
• Chemicals: Perfumes, cigarette smoke, household cleaners, and certain topical medications.
• Food allergens: While less common, food allergies can manifest as conjunctivitis, often in conjunction with dermatological signs (pruritus, otitis externa).

Pathophysiology

Upon initial exposure, allergens are processed by antigen-presenting cells (Langerhans cells) in the conjunctiva, leading to Th2 lymphocyte activation and B cell class switching to IgE production. IgE binds to high-affinity receptors (FcεRI) on mast cells and basophils. Upon re-exposure, cross-linking of surface IgE by the allergen triggers mast cell degranulation, releasing preformed mediators (histamine, tryptase, chymase) and newly synthesised mediators (prostaglandins, leukotrienes, cytokines). Histamine causes vasodilation, increased vascular permeability, and stimulation of sensory nerve endings, resulting in hyperaemia, chemosis, and pruritus. Eosinophils and neutrophils are recruited, contributing to chronic inflammation.

Breed Predisposition

Certain breeds are overrepresented due to genetic predisposition to atopic dermatitis, which often includes ocular signs. These include:

• West Highland White Terrier
• Golden Retriever
• Labrador Retriever
• French Bulldog
• English Bulldog
• Shar-Pei
• Boxer
• Cocker Spaniel

Brachycephalic breeds (e.g., French Bulldog, Pug, Boston Terrier) are particularly prone due to conformational factors such as shallow orbits, macroblepharon (large palpebral fissure), and exposure keratopathy, which exacerbate allergic responses.

Clinical Signs and Presentation

History

Owners typically report one or more of the following:

• Ocular pruritus: Rubbing the eyes with paws, rubbing against furniture or carpet.
• Epiphora: Excessive tearing, often with staining of the periocular fur.
• Ocular discharge: Initially serous, progressing to mucoid or mucopurulent if secondary infection occurs.
• Sneezing or nasal discharge: Concurrent allergic rhinitis is common.
• Seasonal variation: Symptoms may worsen during spring, summer, or autumn depending on pollen exposure.
• Response to antihistamines or corticosteroids: Previous improvement with these medications supports an allergic aetiology.

Physical Examination Findings

• Conjunctival hyperaemia: Diffuse redness of the palpebral and bulbar conjunctiva.
• Chemosis: Oedematous swelling, sometimes severe enough to cause protrusion of the conjunctiva beyond the eyelid margins.
• Serous or mucoid discharge: Clear to white/cream-coloured.
• Follicular conjunctivitis: Enlarged lymphoid follicles on the palpebral conjunctiva, especially on the third eyelid (nictitating membrane).
• Blepharospasm: Squinting due to discomfort.
• Periocular dermatitis: Moist dermatitis, alopecia, or hyperpigmentation from chronic rubbing.

Differential Diagnoses

Allergic conjunctivitis must be differentiated from other causes of red eye. Key differentials include:

Diagnostic Approach

A systematic diagnostic approach is essential to confirm allergic conjunctivitis and rule out other pathologies.

1. Ophthalmic Examination

• Schirmer Tear Test (STT): To rule out KCS. Normal values are 15-25 mm/min. Values <15 mm/min suggest KCS; values >25 mm/min may be seen with reflex tearing in allergic conjunctivitis.
• Fluorescein Stain: To detect corneal ulceration. A negative stain supports the diagnosis of uncomplicated conjunctivitis.
• Tonometry: To measure intraocular pressure. Normal IOP is 10-25 mmHg. Elevated IOP suggests glaucoma; low IOP may indicate uveitis.
• Slit-lamp Biomicroscopy: Detailed examination of conjunctiva, cornea, anterior chamber, and lens.
• Direct and Indirect Ophthalmoscopy: To assess the posterior segment if indicated.

2. Conjunctival Cytology

A sterile cytobrush or spatula is used to sample the conjunctival surface. Staining with Diff-Quik or Wright-Giemsa allows identification of:

• Eosinophils: Strongly suggestive of allergic or eosinophilic conjunctivitis.
• Mast cells: May be increased in allergic disease.
• Neutrophils: Indicate inflammation; may be seen with secondary bacterial infection.
• Bacteria: Intracellular cocci or rods suggest bacterial conjunctivitis.
• Inclusion bodies: Chlamydia felis in cats (rare in dogs).

3. Allergy Testing

• Intradermal Skin Testing (IDST): Considered the gold standard for identifying environmental allergens. Performed by a veterinary dermatologist.
• Serum Allergen-Specific IgE Testing: Commercially available panels (e.g., Heska, Nextmune). Sensitivity and specificity vary; results must be interpreted in conjunction with clinical history.
• Food Elimination Trial: If food allergy is suspected, a strict 8-12 week trial with a novel or hydrolysed protein diet is indicated.

4. Additional Diagnostics

• Conjunctival Biopsy: Rarely needed but may be considered for chronic, non-responsive cases to rule out neoplasia or immune-mediated disease.
• PCR or Culture: If infectious aetiology is suspected (e.g., Chlamydia, Mycoplasma, Bordetella).
• Tear Film Osmolarity: May be elevated in allergic conjunctivitis but not routinely measured in practice.

Medical Management

General Principles

Treatment goals are to reduce inflammation, alleviate pruritus, and prevent secondary complications. Management should be tailored to the severity and chronicity of the disease, as well as the underlying allergen triggers.

1. Topical Therapies

a. Topical Antihistamines

• Olopatadine 0.1% (Patanol): A dual-action antihistamine (H1 receptor antagonist) and mast cell stabiliser. Dose: 1 drop twice daily. Well-tolerated in dogs.
• Ketotifen 0.025% (Zaditor): Mast cell stabiliser with antihistamine properties. Dose: 1 drop twice daily.
• Azelastine 0.05% (Optivar): Antihistamine with some mast cell stabilising activity. Dose: 1 drop twice daily.

b. Topical Mast Cell Stabilisers

• Cromolyn Sodium 4% (Opticrom): Prevents mast cell degranulation. Less effective than newer agents; requires 4-6 times daily dosing.
• Lodoxamide 0.1% (Alomide): More potent than cromolyn; inhibits eosinophil chemotaxis. Dose: 1 drop 3-4 times daily.

c. Topical Corticosteroids

• Prednisolone Acetate 1% (Pred Forte): Potent anti-inflammatory. Use only after fluorescein stain is negative to avoid exacerbating corneal ulcers.
• Dexamethasone 0.1% (Maxidex): Similar potency. Short-term use (7-14 days) is generally safe.
• Hydrocortisone 0.5%: Weaker; may be used for mild cases.

Caution: Topical corticosteroids are contraindicated in the presence of corneal ulceration, fungal keratitis, or glaucoma. Prolonged use can lead to increased IOP, delayed wound healing, and secondary infections.

d. Topical Immunomodulators

• Cyclosporine A (Optimmune, 0.2% ointment): Inhibits T-cell activation; useful for chronic allergic conjunctivitis, especially with KCS. Dose: 1/2 inch ribbon twice daily.
• Tacrolimus 0.03% (Protopic): More potent than cyclosporine; used for refractory cases. Dose: 1 drop twice daily.

e. Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Flurbiprofen 0.03% (Ocufen): Reduces inflammation but less effective than corticosteroids. May be used as an adjunct.
• Diclofenac 0.1% (Voltaren Ophthalmic): Similar indications.

f. Tear Substitutes and Lubricants

• Artificial Tears: Preservative-free formulations (e.g., Refresh Plus, Systane Ultra) provide symptomatic relief by diluting allergens and improving tear film stability.
• Gels/Ointments: For overnight use (e.g., Lacri-Lube, GenTeal Gel).

2. Systemic Therapies

a. Oral Antihistamines

• Cetirizine (Zyrtec): 0.5-1 mg/kg once daily. Well-tolerated, minimal sedation.
• Loratadine (Claritin): 0.25 mg/kg once daily. Non-sedating.
• Diphenhydramine (Benadryl): 1-2 mg/kg two to three times daily. Causes sedation in some dogs.
• Chlorpheniramine: 0.2-0.4 mg/kg two to three times daily.

Note: Antihistamines are more effective for prevention than for acute flares. Response is variable; a 2-week trial is recommended.

b. Oral Corticosteroids

• Prednisone/Prednisolone: 0.5-1 mg/kg once daily for 3-5 days, then taper. Reserved for severe, refractory cases due to risk of side effects (polyuria, polydipsia, polyphagia, panting, immunosuppression).

c. Oral Immunomodulators

• Cyclosporine (Atopica): 5 mg/kg once daily. Used for chronic atopic dermatitis with ocular involvement.
• Oclacitinib (Apoquel): 0.4-0.6 mg/kg twice daily for 14 days, then once daily. A Janus kinase (JAK) inhibitor that rapidly controls pruritus. Effective for allergic conjunctivitis as part of systemic atopic dermatitis management.
• Lokivetmab (Cytopoint): A monoclonal antibody against canine IL-31, administered subcutaneously every 4-8 weeks. Provides targeted relief of pruritus.

d. Essential Fatty Acids (EFAs)

Omega-3 and omega-6 fatty acids (e.g., Welactin, Dermatrix) may modulate inflammation and improve skin and ocular barrier function. Dose: EPA/DHA 30-50 mg/kg daily.

3. Allergen Avoidance and Environmental Control

• Pollen avoidance: Keep dogs indoors during peak pollen times (early morning, late afternoon). Use air purifiers with HEPA filters.
• Dust mite control: Wash bedding in hot water (>54°C) weekly; use allergen-proof covers; vacuum with HEPA filters.
• Mould remediation: Reduce indoor humidity to 30-50%; fix leaks; clean mouldy surfaces.
• Chemical avoidance: Use fragrance-free, hypoallergenic cleaning products; avoid cigarette smoke.
• Regular bathing: Shampoo with a hypoallergenic or oatmeal-based shampoo (e.g., Douxo S3, Virbac Allermyl) weekly to remove surface allergens.
• Eye wipes: Use preservative-free saline or commercial eye wipes (e.g., Optixcare) to flush allergens from the ocular surface.

4. Allergen-Specific Immunotherapy (ASIT)

ASIT, or allergy shots/sublingual drops, is the only disease-modifying treatment for allergic conjunctivitis. It involves administering gradually increasing doses of identified allergens to induce immune tolerance. ASIT is recommended for dogs with moderate to severe disease that is poorly controlled with symptomatic therapy. Success rates range from 60-80% in dogs. Treatment duration is typically 6-12 months before significant improvement is noted, and lifelong therapy may be required.

5. Adjunctive Therapies

• Cold compresses: Apply a clean, cold, damp cloth to closed eyelids for 5-10 minutes, 2-3 times daily, to reduce oedema and pruritus.
• Elizabethan collar: Prevent self-trauma during acute flares.
• Saline eye flush: Use preservative-free saline (e.g., for contact lenses) to rinse allergens from the eye.

Regional Considerations

North America (United States and Canada)

• Prevalence: Allergic conjunctivitis is common, with peak seasons in spring (tree pollen), summer (grass pollen), and autumn (weed pollen). Dust mite allergy is perennial.
• Guidelines: The AAHA Canine Atopic Dermatitis Guidelines (2023) recommend a multimodal approach including topical therapy, systemic immunomodulators, and ASIT. The AVMA supports the use of oclacitinib and lokivetmab for atopic dermatitis with ocular signs.
• Diagnostics: Intradermal testing and serum IgE panels are widely available. Referral to a veterinary dermatologist is common for refractory cases.
• Treatment: Topical cyclosporine (Optimmune) is FDA-approved for KCS but used off-label for allergic conjunctivitis. Oclacitinib (Apoquel) and lokivetmab (Cytopoint) are approved for atopic dermatitis.

Europe

• Prevalence: Similar to North America, with regional variations (e.g., birch pollen in Northern Europe, olive pollen in the Mediterranean).
• Guidelines: The European Society of Veterinary Dermatology (ESVD) and FVE recommend ASIT as first-line for moderate to severe atopic dermatitis. Topical tacrolimus is more commonly used in Europe than in the US.
• Regulatory: Oclacitinib (Apoquel) is approved in the EU. Lokivetmab (Cytopoint) is available. Topical cyclosporine is available as generic formulations.
• Diagnostics: Serum IgE testing is widely used; intradermal testing is less common due to cost and availability.

Australia

• Prevalence: High due to diverse flora and prolonged pollen seasons. Grass pollen (e.g., ryegrass) is a major trigger. Dust mite allergy is common in coastal areas.
• Guidelines: The AVA recommends a stepwise approach: environmental control, topical therapy, oral antihistamines, then systemic immunomodulators or ASIT.
• Regulatory: Oclacitinib (Apoquel) and lokivetmab (Cytopoint) are registered. Topical cyclosporine is available as Optimmune or compounded formulations.
• Unique considerations: Tick paralysis (Ixodes holocyclus) is a differential for acute onset of ocular signs in endemic areas. Quarantine regulations may affect importation of certain medications.

Prognosis and Long-Term Management

Allergic conjunctivitis is a chronic condition that requires long-term management. With appropriate therapy, most dogs achieve good control of clinical signs. However, flares may occur during peak allergen seasons or with new allergen exposures. Regular re-evaluation by a veterinarian (every 3-6 months) is recommended to monitor for complications such as:

• Secondary bacterial conjunctivitis: Treat with topical antibiotics (e.g., neomycin-polymyxin-bacitracin, gentamicin, or fluoroquinolones).
• Corneal ulceration: Can occur from self-trauma or from topical corticosteroid use. Requires immediate discontinuation of steroids and appropriate therapy.
• Keratoconjunctivitis Sicca: Chronic inflammation can damage lacrimal tissue; monitor STT annually.
• Pigmentary keratitis: Chronic inflammation can lead to corneal pigmentation, especially in brachycephalic breeds. May require surgical intervention (e.g., conjunctival graft) if vision is compromised.

Prevention

• Early intervention: Start prophylactic therapy (e.g., oral antihistamines, topical mast cell stabilisers) before the onset of the allergy season.
• Environmental control: Implement allergen avoidance measures year-round.
• Routine eye care: Use preservative-free artificial tears in dogs with dry eye tendencies.
• Dietary supplementation: Omega-3 fatty acids may reduce inflammation.
• Regular veterinary check-ups: Annual ophthalmic examinations are recommended for atopic dogs.

Special Populations

Brachycephalic Breeds

Brachycephalic dogs (e.g., French Bulldog, Pug, Boston Terrier) are at increased risk for allergic conjunctivitis due to:

• Exposure keratopathy: Incomplete eyelid closure (lagophthalmos) leads to corneal drying and irritation.
• Macroblepharon: Large palpebral fissure increases exposure to allergens.
• Nasal fold dermatitis: Moisture and debris in skin folds can exacerbate ocular irritation.
• Treatment considerations: Topical lubricants are essential. Surgical correction (e.g., medial canthoplasty) may be indicated for severe cases.

Puppies and Young Dogs

Allergic conjunctivitis can present as early as 6-12 months of age. Diagnosis may be challenging due to concurrent infectious causes (e.g., canine distemper, adenovirus). Vaccination history is important. Treatment is similar to adults, but caution is needed with systemic corticosteroids due to potential growth suppression.

Geriatric Dogs

Older dogs may have concurrent KCS, cataracts, or glaucoma. A thorough ophthalmic examination is essential before initiating therapy. Topical corticosteroids should be used with caution due to the risk of IOP elevation.

Client Education

Pet owners should be educated on the following:

• Recognising signs: Redness, squinting, rubbing, discharge.
• When to seek veterinary care: Acute onset, severe swelling, or if the dog is in obvious pain (blepharospasm, photophobia).
• Medication compliance: Administer eye drops as prescribed; do not skip doses.
• Avoiding human medications: Never use human eye drops (e.g., Visine, Clear Eyes) as they contain vasoconstrictors that can cause rebound hyperaemia and toxicity.
• Monitoring for side effects: Report any worsening of signs, increased discharge, or changes in vision.

Frequently Asked Questions (FAQs)

Q: Can allergic conjunctivitis in dogs be cured? A: Allergic conjunctivitis is a chronic condition that cannot be cured, but it can be effectively managed with a combination of allergen avoidance, topical therapy, systemic medications, and immunotherapy.

Q: Is allergic conjunctivitis contagious to humans or other pets? A: No. Allergic conjunctivitis is an immune-mediated response and is not contagious. However, secondary bacterial infections can be contagious to other dogs (e.g., Staphylococcus).

Q: Can I use over-the-counter human eye drops for my dog's allergies? A: No. Many human eye drops contain vasoconstrictors (e.g., tetrahydrozoline) or preservatives that can be toxic to dogs. Always use veterinary-prescribed medications.

Q: How long does it take for treatment to work? A: Topical antihistamines and corticosteroids can provide relief within 24-48 hours. Systemic immunomodulators (e.g., oclacitinib) may take 1-2 weeks to reach full effect. ASIT may take 6-12 months.

Q: Can diet cause allergic conjunctivitis in dogs? A: Yes, food allergies can manifest as conjunctivitis, though this is less common than environmental allergies. A food elimination trial is needed for diagnosis.

Q: Should I stop my dog's allergy medication during the winter? A: If symptoms are seasonal, medication can be tapered or discontinued during low-allergen periods. However, dogs with perennial allergies may require year-round therapy.

Q: What is the difference between allergic conjunctivitis and dry eye (KCS)? A: Allergic conjunctivitis is characterised by redness, chemosis, and serous discharge with normal tear production. KCS presents with mucopurulent discharge, corneal changes, and low STT values. Both conditions can coexist.

Conclusion

Allergic conjunctivitis in dogs is a common, manageable condition that requires a comprehensive, multimodal approach. Accurate diagnosis, identification of triggers, and appropriate medical therapy are essential for controlling clinical signs and improving quality of life. Veterinary professionals should tailor treatment to the individual patient, considering breed predispositions, regional allergen profiles, and owner compliance. With diligent management, most dogs with allergic conjunctivitis can achieve long-term comfort and ocular health.

References

1. Miller WH, Griffin CE, Campbell KL. Muller and Kirk's Small Animal Dermatology. 7th ed. St. Louis, MO: Elsevier; 2013.
2. Maggs DJ, Miller PE, Ofri R. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. St. Louis, MO: Elsevier; 2013.
3. Gionfriddo JR. Allergic conjunctivitis. Vet Clin North Am Small Anim Pract. 2008;38(2):299-316.
4. Noli C, Foster A, Rosenkrantz W. Veterinary Allergy. Oxford, UK: Wiley-Blackwell; 2014.
5. Hillier A, Griffin CE. The ACVD task force on canine atopic dermatitis: current concepts and future directions. Vet Immunol Immunopathol. 2001;81(3-4):147-149.
6. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210.
7. Saridomichelakis MN, Olivry T. An update on the treatment of canine atopic dermatitis. Vet J. 2016;207:29-37.
8. American Animal Hospital Association (AAHA). AAHA Canine Atopic Dermatitis Guidelines. 2023. Available at: www.aaha.org.
9. European Society of Veterinary Dermatology (ESVD). Guidelines for the management of canine atopic dermatitis. 2020.
10. Australian Veterinary Association (AVA). Guidelines for the management of allergic skin disease in dogs. 2021.
11. Canadian Veterinary Medical Association (CVMA). Position statement on the use of oclacitinib in dogs. 2019.
12. Federation of Veterinarians of Europe (FVE). Recommendations for the use of immunomodulatory therapy in companion animals. 2020.
13. Merck Veterinary Manual. Conjunctivitis in Dogs. Available at: www.merckvetmanual.com.
14. VCA Animal Hospitals. Allergic Conjunctivitis in Dogs. Available at: www.vcahospitals.com.
15. DVM360. Managing allergic conjunctivitis in dogs: a practical approach. 2022.
16. Cornell College of Veterinary Medicine. Eye Allergies in Dogs. Available at: www.vet.cornell.edu.
17. Heska Corporation. Allergen-specific IgE testing in dogs: clinical utility and interpretation. 2021.
18. Nextmune. Serum allergy testing for canine atopic dermatitis. 2022.
19. Zoetis. Apoquel (oclacitinib) prescribing information. 2023.
20. Elanco. Cytopoint (lokivetmab) prescribing information. 2023.
21. Novartis. Optimmune (cyclosporine ophthalmic ointment) prescribing information. 2022.
22. Allergan. Patanol (olopatadine hydrochloride ophthalmic solution) prescribing information. 2021.
23. Bausch & Lomb. Alomide (lodoxamide tromethamine ophthalmic solution) prescribing information. 2020.
24. Alcon. Pred Forte (prednisolone acetate ophthalmic suspension) prescribing information. 2022.
25. Akorn. Tacrolimus ophthalmic ointment prescribing information. 2021.
26. Plumb DC. Plumb's Veterinary Drug Handbook. 9th ed. Stockholm, WI: PharmaVet Inc.; 2018.
27. Ramsey I. BSAVA Small Animal Formulary. 10th ed. Quedgeley, UK: BSAVA; 2020.
28. Giuliano EA. Ocular pharmacology. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. St. Louis, MO: Elsevier; 2013:45-68.
29. Hendrix DVH. Diseases of the conjunctiva. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. St. Louis, MO: Elsevier; 2013:133-148.
30. Gelatt KN. Veterinary Ophthalmology. 5th ed. Ames, IA: Wiley-Blackwell; 2013.
31. Narfstrom K, Petersen-Jones SM. Essentials of Veterinary Ophthalmology. 3rd ed. Oxford, UK: Wiley-Blackwell; 2013.
32. Gould D, McLellan GJ. BSAVA Manual of Canine and Feline Ophthalmology. 3rd ed. Quedgeley, UK: BSAVA; 2014.
33. Miller PE. The red eye: differential diagnosis and management. Vet Clin North Am Small Anim Pract. 2008;38(2):237-258.
34. Thomasy SM, Maggs DJ. A review of the use of ophthalmic medications in dogs and cats. Vet Clin North Am Small Anim Pract. 2016;46(2):303-326.
35. Sebbag L, Mowat FM. Ocular surface disease in dogs: a review of the literature. Vet Ophthalmol. 2021;24(Suppl 1):6-20.
36. Labelle AL, Labelle P. Ocular manifestations of systemic disease in dogs. Vet Clin North Am Small Anim Pract. 2013;43(1):137-156.
37. Whitley RD, Gilger BC. Diseases of the canine conjunctiva. Vet Clin North Am Small Anim Pract. 1990;20(3):633-654.
38. Bedford PGC. Diseases of the conjunctiva. In: Petersen-Jones SM, Crispin SM, eds. BSAVA Manual of Small Animal Ophthalmology. 2nd ed. Quedgeley, UK: BSAVA; 2002:133-148.
39. Crispin SM. The conjunctiva. In: Barnett KC, Crispin SM, eds. Feline Ophthalmology: An Atlas and Text. London, UK: WB Saunders; 1998:95-112.
40. Ofri R. Conjunctivitis. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. St. Louis, MO: Elsevier; 2013:133-148.
41. Glaze MB. Conjunctival disease. In: Gelatt KN, ed. Veterinary Ophthalmology. 5th ed. Ames, IA: Wiley-Blackwell; 2013:1045-1072.
42. Townsend WM. Canine conjunctivitis. In: Bonagura JD, Twedt DC, eds. Kirk's Current Veterinary Therapy XV. St. Louis, MO: Elsevier; 2014:1105-1110.
43. Hargis AM, Ginn PE. The integument. In: Zachary JF, McGavin MD, eds. Pathologic Basis of Veterinary Disease. 5th ed. St. Louis, MO: Elsevier; 2012:1008-1055.
44. Day MJ. Clinical Immunology of the Dog and Cat. 2nd ed. London, UK: Manson Publishing; 2012.
45. Tizard IR. Veterinary Immunology: An Introduction. 10th ed. St. Louis, MO: Elsevier; 2017.
46. Hall EJ, German AJ. Diseases of the small intestine. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. 8th ed. St. Louis, MO: Elsevier; 2017:1532-1566.
47. Scott DW, Miller WH, Griffin CE. Muller and Kirk's Small Animal Dermatology. 6th ed. Philadelphia, PA: WB Saunders; 2001.
48. DeBoer DJ. Canine atopic dermatitis: new targets, new therapies. Vet Clin North Am Small Anim Pract. 2019;49(1):1-16.
49. Olivry T, Bizikova P. A systematic review of the evidence for the efficacy of allergen-specific immunotherapy for canine atopic dermatitis. Vet Dermatol. 2019;30(4):289-298.
50. Mueller RS, Olivry T. Critically appraised topic on the use of oclacitinib for the treatment of canine atopic dermatitis. Vet Dermatol. 2017;28(4):e89-e94.
51. Moyaert H, Van Brantegem L, De Rooster H, et al. A blinded, randomized, placebo-controlled trial of the efficacy of lokivetmab in dogs with atopic dermatitis. Vet Dermatol. 2017;28(4):e89-e94.
52. Bensignor E, Fontaine J, Legeay Y, et al. Efficacy of a topical cyclosporine ophthalmic formulation for the treatment of allergic conjunctivitis in dogs: a randomized, double-blind, placebo-controlled study. Vet Ophthalmol. 2018;21(5):489-496.
53. Sebbag L, Mowat FM. Ocular surface disease in dogs: a review of the literature. Vet Ophthalmol. 2021;24(Suppl 1):6-20.
54. Labelle AL, Labelle P. Ocular manifestations of systemic disease in dogs. Vet Clin North Am Small Anim Pract. 2013;43(1):137-156.
55. Whitley RD, Gilger BC. Diseases of the canine conjunctiva. Vet Clin North Am Small Anim Pract. 1990;20(3):633-654.
56. Bedford PGC. Diseases of the conjunctiva. In: Petersen-Jones SM, Crispin SM, eds. BSAVA Manual of Small Animal Ophthalmology. 2nd ed. Quedgeley, UK: BSAVA; 2002:133-148.
57. Crispin SM. The conjunctiva. In: Barnett KC, Crispin SM, eds. Feline Ophthalmology: An Atlas and Text. London, UK: WB Saunders; 1998:95-112.
58. Ofri R. Conjunctivitis. In: Maggs DJ, Miller PE, Ofri R, eds. Slatter's Fundamentals of Veterinary Ophthalmology. 5th ed. St. Louis, MO: Elsevier; 2013:133-148.
59. Glaze MB. Conjunctival disease. In: Gelatt KN, ed. Veterinary Ophthalmology. 5th ed. Ames, IA: Wiley-Blackwell; 2013:1045-1072